Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF) and/or other oral antiviral treatment in chronic hepa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• TENOFOVIR DISOPROXIL FUMARATE (tenofovir disoproxil fumarate)
• Tenofovir alafenamide (tenofovir alafenamide)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Hepatitis B | Phase 2 | Status: COMPLETED | Results posted: 2020-04-09